论文部分内容阅读
目的:观察阿司匹林联合低分子肝素预防妊娠期高血压疾病子痫前期的临床效果。方法:选取2017年10月至2018年12月慈溪巿妇幼保健院收治的妊娠期高血压疾病患者120例为研究对象，根据孕妇意愿及知情同意分为对照组和观察组，每组60例，对照组：从孕11～13n ＋6周开始单一口服阿司匹林100 mg/d，至孕36周或至终止妊娠前5～10 d；观察组：从孕11～13n ＋6周开始每天皮下注射3 075 IU低分子肝素连续2周同时口服阿司匹林100 mg/d，至36周或至终止妊娠前5～10 d。观察比较两组子痫前期发生率、不良妊娠结局及并发症发生情况。n 结果:观察组患者子痫前期发生率、早产发生率、剖宫产发生率、胎儿窘迫发生率、胎盘早剥发生率和新生儿窒息发生率分别为15.00%(9/60)、20.00%(12/60)、36.67%(22/60)、11.67%(7/60)、6.67%(4/60)和1.67%(1/60)，均明显低于对照组的31.57%(19/60)、35.00%(21/60)、55.00%(33/60)、30.00%(18/60)、23.33%(14/60)和15.00%(9/60)(χn 2＝4.658、4.104、4.061、6.113、6.535、6.981，均n P<0.05)。观察组分娩时孕周为(37.88±3.72)周、新生儿体质量为(2.63±0.24)kg，均明显大于对照组的(36.11±3.59)周、(2.13±0.20)kg(n t＝2.652、12.397，均n P<0.05)。观察组患者产后失血、血小板减少、羊水过少和胸腹水发生率分别为5.00%(3/60)、1.67%(1/60)、5.00%(3/60)和16.67%(10/60)，明显低于对照组的25.00%(15/60)、16.67%(21/60)、23.33%(14/60)和15.00%(9/60)(χn 2＝9.411、8.106、8.292、6.981，均n P<0.05)。n 结论:妊娠期高血压疾病患者接受小剂量阿司匹林联合低分子肝素治疗，能够降低子痫前期的发生率，改善不良妊娠结局。“,”Objective:To observe the clinical effects of aspirin combined with low-molecular-weight heparin in the prevention of preeclampsia in patients with hypertension during pregnancy.Methods:From October 2017 to December 2018, 120 patients with hypertension during pregnancy who were treated in the Maternal and Child Health Hospital of Cixi were selected.The patients were divided into control group and observation group according to the wishes of pregnant women and informed consent, with 60 patients in each group.Control group received single oral aspirin 100 mg daily from 11-13n + 6 weeks of pregnancy to 36 weeks of pregnancy or 5-10 days before termination of pregnancy.The observation group received 3075 IU of low-molecular-weight heparin subcutaneous injections daily from 11-13n + 6 weeks of pregnancy for 2 weeks, and was orally given aspirin 100 mg daily for 36 weeks or until 5-10 days before termination of pregnancy.The incidence of preeclampoia, adverse pvegnany outcome and complication of the two groups were observed and compared.n Results:The incidences of preeclampsia, preterm birth, cesarean section, fetal distress, placental abruption and neonatal asphyxia in the observation group were 15.00%, 20.00%, 36.67%, 11.67%, 6.67% and 1.67%, respectively, which were significantly lower than those in the control group (31.57%, 35.00%, 55.00%, 30.00%, 23.33% and 15.00%, χ n 2=4.658, 4.104, 4.061, 6.113, 6.535, 6.981, all n P<0.05). The gestational age at delivery[(37.88±3.72)weeks] and the weight of the newborn [(2.63±0.24)kg] in the observation group were significantly larger than those in the control group[(36.11±3.59)weeks, (2.13±0.20)kg](n t=2.652, 12.397, all n P<0.05). The incidences of postpartum blood loss, thrombocytopenia, oligohydramnios and pleural and ascites in the observation group were 5.00%, 1.67%, 5.00% and 16.67%, respectively, which were significantly lower than those in the control group (25.00%, 16.67%, 23.33% and 15.00%, χn 2=9.411, 8.106, 8.292, 6.981, all n P<0.05).n Conclusion:Low-dose aspirin and low-molecular-weight heparin for patients with hypertension during pregnancy can reduce the incidence of preeclampsia and improve adverse pregnancy outcomes, which is worthy of promotion and application.